Laghu Udyog Bharati has requested the government to relax mandatory bio-equivalence study rules for established medicines. The industry body cites high costs of up to ₹50 lakh per product, which may pressure margins for smaller pharmaceutical firms. Investors should track if the government provides exemptions or a transition roadmap, as this could impact the operational expenses and compliance burden for many mid-sized drug makers.
A prominent industry group representing small and medium-sized pharmaceutical enterprises in India has formally requested the central government to reconsider recent mandates regarding drug testing. Laghu Udyog Bharati, which advocates for over 1,260 small and medium-scale manufacturers, has approached Union Health Minister J P Nadda to address the challenges posed by new bio-equivalence study requirements for existing medications.
Impact of Compliance Costs on Smaller Players
Bio-equivalence studies are used to confirm that a generic drug performs the same as the original brand-name version. While these studies are crucial for quality assurance, the industry body reports that the current directives create a heavy financial load. The association estimates that conducting these studies can cost between ₹25 lakh and ₹50 lakh for each product. For smaller firms with diverse portfolios of established medicines, these expenses could significantly weigh on profit margins and cash flow. The LUB argues that applying these strict requirements to legacy medicines, which have already been in use for years, may be impractical.
Proposed Regulatory Adjustments
The industry body has recommended that the government make these bio-equivalence mandates applicable only to new drugs entering the market moving forward. They believe a prospective approach would allow manufacturers to focus their resources on innovation and research for new products rather than repeating testing for thousands of older, proven medicines. Additionally, the association has requested a long-term, 10-year roadmap to help the sector gradually align with higher standards without disrupting supply chains.
Export Concerns and Market Reputation
Beyond testing mandates, the association is seeking a more efficient system for international trade. Manufacturers are calling for an official, government-compiled list of drugs that are restricted or banned in key export markets. Access to such a list would help companies avoid the risk of shipping prohibited products, thereby reducing the need for costly pre-shipment approvals.
Furthermore, the group has raised concerns regarding how drug quality reports are publicized. Currently, regulators publish monthly lists of medicines labeled as 'not of standard quality.' The industry body argues that this practice can sometimes lead to unfair scrutiny of genuine manufacturers. To ensure balance, they have proposed that the government also publish a regular list of companies whose products meet standard quality requirements, aiming to promote transparency in the sector. The next important monitorable for investors will be any official notification or amendment from the Central Drugs Standard Control Organisation regarding these study timelines or compliance exemptions.